About ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gruppo Italiano Malattie EMatologiche dell'Adulto
34
Fondazione Italiana Linfomi ONLUS
15
Hoffmann-La Roche
7
Celgene
4
Incyte Corporation
1
Clinical Trials at ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
During the past decade, ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 10 clinical trials were completed, i.e. on
average, 37% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 2 clinical trials were completed. i.e. 20%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
2006-09-04
2011-05-26
Completed
545
Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
2007-05-01
2011-06-01
Completed
86
"Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients
2007-11-01
2020-01-28
Completed
102
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
2008-04-01
2016-02-01
Completed
150
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
2008-08-21
2016-07-14
Completed
1,623
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
2008-10-02
2021-02-01
Unknown status
927
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
2009-10-19
2017-09-05
Completed
104
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 34 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 15 trials
sponsored, "Hoffmann-La Roche" with 7 trials sponsored, "Celgene" with 4 trials sponsored and "Incyte Corporation"
with 4 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE"
#1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
According to Clinical.Site data, the most researched conditions in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE" are
"Chronic Myeloid Leukemia" (4 trials), "Acute Lymphoblastic Leukemia" (3 trials), "Breast Cancer" (3 trials), "Hodgkin Lymphoma" (3 trials) and "Leukemia" (3 trials). Many other conditions were trialed in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE" in a lesser frequency.
Clinical Trials Intervention Types at ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
Most popular intervention types in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE" are "Drug" (46 trials), "Other" (8 trials), "Procedure" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "Fludarabine" (3 trials), "Ponatinib" (3 trials), "Rituximab" (3 trials), "Bendamustine" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.
Clinical Trials Genders at ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
The vast majority of trials in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE" are
60 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
Currently, there are NaN active trials in "ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE".
2 are not yet recruiting,
10 are recruiting,
11 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 28 completed trials in ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, 1 "Phase 1"
clinical trials were conducted, 23 "Phase 2" clinical
trials and 12 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 3 trials that are defined as “Not Applicable".